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Post-traumatic stress disorder (PTSD) is a psychiatric disorder that causes significant
functional impairment and is related to altered stress response and reinforced learned
fear behavior. PTSD has been found to impact three functional networks in the brain:
default mode, executive control, and salience. The executive control network includes
the dorsolateral prefrontal cortex (DLPFC) and lateral PPC. The salience network involves
the anterior cingulate cortex, anterior insula, and amygdala. This latter network has
been found to have increased functional connectivity in PTSD. Transcranial Magnetic
Stimulation (TMS) is a technique used in treating PTSD and involves stimulating specific
portions of the brain through electromagnetic induction. Currently, high-frequency TMS
applied to the left dorsolateral prefrontal cortex (DLPFC) is approved for use in treating
major depressive disorder (MDD) in patients who have failed at least one medication
trial. In current studies, high-frequency stimulation has been shown to be more effective
in PTSD rating scales posttreatment than low-frequency stimulation. The most common
side effect is headache and scalp pain treated by mild analgesics. Seizures are a rare side
effect and are usually due to predisposing factors. Studies have been done to assess the
overall efficacy of TMS. However, results have been conflicting, and sample sizes were
small. More research should be done with larger sample sizes to test the efficacy of
TMS in the treatment of PTSD. Overall, TMS is a relatively safe treatment. Currently, the
only FDA- approved to treat refractory depression, but with the potential to treat many
other conditions.
Keywords: PTSD, Transcranial Magnetic Stimulation, anxiety, neurobiological treatment, Post-traumatic stress
disorder

INTRODUCTION
Post-traumatic stress disorder (PTSD) is classified as a “trauma and stressor-related disorder” in
the Diagnostic and Statistical Manual (DSM-5) (1). About 7–9% of the general population develop
PTSD in their lifetime (2). Patients diagnosed with PTSD often have poorer social support and
higher rates of occupational, financial, and health problems (3). In addition, these patients are
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personnel have a higher incidence of overall PTSD prevalence,
with up to 30% of veterans experiencing PTSD and 15%
continuing to experience symptoms 10 years after the conclusion
of war (10). These numbers tend to vary between studies.
However, the consensus is that there is a larger percentage
of those who have combat and military associated traumatic
experience with PTSD compared to the civilian population.
Most people do not develop PTSD after exposure to trauma.
While risk factors for PTSD do play a role, the most significant
factor is the severity of the trauma. Some events such as rape
or direct combat are associated with rates of PTSD up to 50%
(21). Other differences within the population are the prevalence
in women compared to men. Despite fewer exposures to trauma,
women are at higher risk with a lifetime prevalence of 20.4%
compared to men at 8.2% (9).

at increased risk for attempting suicide and have more frequent
marital difficulties and intimate relationship problems (4–6).
This manuscript aims to look at PTSD as well as Transcranial
Magnetic Stimulation (TMS) which is an alternative treatment
for PTSD symptoms.

Diagnostic Definition and Clinical
Presentation
The following criteria are required for the diagnosis of PTSD
(1). To meet criterion A, a person must have been exposed
to one or more traumatic events. If criterion A is met, the
person must present with clustered symptoms that satisfy
criteria B-E. The symptom clusters are intrusion, avoidance,
negative alterations in cognitions and mood, and alterations in
arousal and reactivity. An intrusive symptom can be distressing
memories, recurrent distressing dreams, dissociative reactions
(e.g., flashbacks), or intense or prolonged psychological distress
when exposed to reminders of the trauma. Next, a person must
present with avoidance symptoms related to the traumatic event.
This includes avoidance of internal reminders (thoughts and
memories) or active avoidance of external reminders (people,
places, activities, etc.). A person must present with two symptoms
which could include negative alterations in cognitions and mood.
This includes an inability to remember an important aspect
of the traumatic event; persistent and exaggerated negative
thoughts about oneself, others or the world, persistent and
distorted cognitions about the cause or consequences of the
event; persistent negative emotions; diminished interest in
activities, feeling detached from others, and/or a persistent
inability to experience positive emotions. Finally, a person
must present with two arousal symptoms which can include
irritable behavior and angry outbursts, reckless or self-destructive
behavior, hypervigilance, exaggerated startle response, problems
with concentration, and/or sleep disturbances. These symptoms
must be present for 1 month or longer following the trauma.
The presentation of PTSD is variable between individuals
but must include one example from each domain. Symptoms
present within 3 months and persist for longer than 1 month and
may be intermittent. Other than these 4 categories of symptoms,
individuals may also experience somatic manifestations that
resemble physical illness and can affect various systems
such as musculoskeletal, nervous, cardiac, respiratory, and
gastrointestinal (7). Following a trauma, it is normal to
experience distress, but individuals with PTSD are not able
to decrease their fear of certain triggers and confront certain
stimuli leading to the development of avoidance strategies in
order to prevent distressing emotions and stimuli. These feelings
and behavioral changes are found in each of the four clusters
of symptoms.

Risk Factors
Genetic Factors
Twin studies have shown genetic influences play a role in
the development of PTSD, accounting for a 30-72% of the
vulnerability to develop PTSD (22–24). In addition, twin
studies have demonstrated the comorbidity of PTSD with other
mental disorders such as Major Depressive Disorder, Generalized
Anxiety Disorder, Panic Disorder, and Substance Use Disorder
(25). Candidate gene studies have largely focused on the genes
involved in the Hypothalamic-Pituitary-Adrenal axis, with over
50 gene variants linked with PTSD (26, 27). However, candidate
gene studies have shown mixed results and attention has turned
toward Genome Wide Association Studies, which have identified
common variants and novel loci, not previously identified by
biologic studies (27, 28). Research has started to look at epigenetic
processes as well, mostly focused on DNA methylation, which has
identified a number of implicated genes (29, 30).

Risk Factors Associated With PTSD Beyond Neural
Networks
Not everyone who experiences trauma develops PTSD; however,
those who do are vulnerable and possess risk factors. Directly
associated with the ability to handle the stress response is the
idea of resilience, which is the ability to adapt successfully in
response to adversity, trauma, or significant threat. The lack
of resilience and presence of various risk factors are involved
in the development of PTSD. The risk factors are broken into
three categories including pre-trauma, peri-trauma and posttrauma (7).
Pre-traumatic risk factors include characteristics such as
demographics, health history, neurobiological, and cognitive
characteristics. Females are twice as likely to be affected and have
symptoms for a longer duration and poorer quality of life. Age
also plays a role with the lowest incidence found in those older
than 60 and the highest incidence found in individuals aged 45–
59. IQ has been found to be inversely correlated with the risk of
PTSD and high IQ is potentially a protective factor in traumaexposed individuals. Sexual minorities are at greater risk related
to higher rates of early childhood abuse and greater exposure
to violence and to traumatic events. Other pre-trauma risk
factors include psychopathology and familial psychiatric history,

Epidemiology
PTSD has a lifetime prevalence of 7–12% in the US (8). As
one of the only psychiatric conditions with an identifiable cause,
PTSD is often seen in those who have experienced trauma. These
include combat, personal assault, natural disasters, motor vehicle
accidents, rape, childhood physical and sexual abuse, loss of loved
ones, and medical crises (9). Compared to civilians, military
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or enhanced in PTSD. The default mode network is comprised
of regions including the MPFC, PCC, PPC, and TC. The
default mode network is the network of brain regions that is
active when the brain is at “rest” (not sleeping), and involves
interoceptive processing of information that pertains to oneself
as well as episodic memory. This network has been found to
have reduced connectivity in PTSD, observed in relation to
memory dysfunction and processing of fear (2). The executive
control network includes the DLPFC and lateral PPC, which are
also disrupted in PTSD (11). Normally, this network regulates
executive function, particularly emotion regulation and working
memory. Lastly, the salience network involves the anterior
cingulate cortex, anterior insula, and amygdala. It has been found
to have increased functional connectivity in PTSD. Since this
network is responsible for the detection of environmental stimuli,
this upregulation in activity is observed as increased threat
detection (35). The network relationships that vary between
individuals may play a role in the severity of symptoms and
individual experience (35). In addition, these varying networks
are useful as a clinical measure for the evaluation of PTSD
symptoms and can predict response to treatment (36).
A recent neuroimaging study found that there were aberrant
connections in a treatment-resistant form of PTSD. They
found that a subgroup in their study displayed both aberrant
connections in the ventral attention network (VAN) as seen
on fMRI and impaired verbal memory on a word list learning
task (37). This phenotype could be used to predict a poor
response to psychotherapy. These authors also used focal
TMS and electroencephalography they identified alterations in
the neurosignal flow in the VAN that was evoked by direct
stimulation of that network (37). They concluded that their
findings identified neurobiological mechanisms in a subgroup
of patients with PTSD that could be responsible for the poor
response to psychotherapy.

specifically the risk is increased in anxious individuals and early
onset mood disorders (7). Lastly, certain races and ethnicities
have been found to have a higher association with PTSD with
Blacks and Hispanics with the highest lifetime prevalence and
Asians with the lowest (31).
Peritraumatic risk factors are critical in assessing the risk
of developing PTSD and include trauma type and severity.
There is a higher association of PTSD with sexual assault or
physical injury. Associated with this is how one perceives the
trauma. If an individual deems that the incident involved is
a true threat to one’s life or led to significant losses, they are
at greater risk of developing PTSD. For example, the military
previously utilized debriefing sessions immediately after trauma
in an attempt to promote emotional processing. Although these
sessions were created in an attempt to prevent maladaptive
emotional outcomes, by encouraging sudden recollection of the
event there was an observed increase in PTSD as these debriefing
sessions led to re-traumatization (32). Additionally, included in
the peri-traumatic period is how one processes their trauma. An
individual is less likely to develop PTSD if they perceive their
experience as having ended vs. if they feel a continued threat and
are unable to disengage from their traumatic experience (7).
Lastly, there are posttraumatic factors that predispose
individuals to developing PTSD. Psychosocial factors are
associated with coping with stress and include optimism,
cognitive flexibility, and active coping skills. Cognitive flexibility
or rigidity is important in the processing of traumatic events and
can alter the likelihood of resilient outcomes vs. psychopathology.
This processing pertains to how one interprets trauma and is
able to reevaluate their perception and experience of the trauma.
Following a trauma, if one generalizes their experience this
may lead to inflexibility and development of PTSD symptoms.
Access to needed resources such as psychological first aid,
protection from further harm, connection to required services
all are protective against the development of PTSD. Addressing
an individual’s needs and concerns through compassion and
support is protective as well as allowing for the normalization
of one’s emotional response (33). The presence of social support
networks is important; the lack of a social support system in
addition to ongoing life stress can increase the risk of developing
PTSD. Physical activity has been found to boost resilience and
is considered to be a protective factor. The presence of mature
defense mechanisms such as altruism produces psychological and
physiological benefits assists in the post-traumatic period and can
confer resilience (7, 34).
Pathophysiology: Neural Networks, Relevant Brain Structures
Further Explained, HPA Axis and Sympathetic Nervous System

Pathophysiology: Relevant Brain Structures Further
Explained
Another approach to the pathophysiology of PTSD involves
understanding the different brain regions involved in the
stress response. Generally, the current understanding of PTSD
is hyperactivity of deeper structures and hypoactivity of the
prefrontal cortex. These deeper structures include the amygdala
and hippocampus and are involved in memory consolidation and
fear circuitry (2, 11, 38). The prefrontal cortex can be subdivided
into regions and the ventromedial prefrontal cortex (VMPFC)
and DLPFC have been implicated in PTSD. The VMPFC plays a
role in emotional regulation and suppression of the fear response
and the DLPFC in executive functioning (2, 11).
In PTSD, the amygdala is hyperactive in response to negative
stimuli and neutral stimuli, while exhibiting a lesser response to
positive stimuli. The amygdala is an important contributor to the
reward system and decision making in terms of behavior (39).
There are connections that run from the amygdala to the nucleus
accumbens, which is the main reward system responsible for
reinforcing behaviors (39). This finding explains the amygdala’s
role in PTSD, specifically how emotional processing and
reward reinforcement create abnormal behavioral and emotional

Pathophysiology: Neural Networks
PTSD is believed to be related to abnormal stress response and
fear learning, that in turn impact three cerebrocortical networks:
the default mode, the executive control, and salience networks.
PTSD involves the derangement of a multitude of pathways
and structures that normally work in synchrony to properly
process stress. Each neural network involves different brain
structures, has diverse responsibilities, and is either disrupted
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changes in response to triggers; these abnormal behaviors and
emotional changes are learned and then reinforced overtime.
Additionally, the amygdala has been found to be coactivated
with the hippocampus when exposed to negative stimuli. The
hippocampus was also found to be enhanced in response to
negative content and this increased activity was found to be
related to worse memory performance. Altogether, this finding
may not only explain the overgeneralization of fear in PTSD,
as there is enhanced hippocampus activity, but also altered
memory accuracy.
Lastly, certain regions of the prefrontal cortex are important
players in the pathophysiology of PTSD. The medial structures
of the cortex are activated in response to emotional triggers. The
VMPFC is heavily connected to the amygdala and acts to regulate
emotion. The activity of the VMPFC is diminished in PTSD
leading to increased activation and reactivity of the amygdala
since it a role in the inhibitory control over the amygdala (40).
Additionally, the VMPFC can alter the original fear that led
to the development of PTSD and instead override it with safe
memories (9). The DLPFC is involved in complex cognitive and
behavioral functions. These functions include working memory,
attention control, decision-making, and behavioral organization.
There is an indirect connection involved in regulation of the
mood network comprised of the amygdala and hippocampus. In
PTSD, the DLPFC is hypoactive, and similar to the VMPFC leads
to hyper reactivity of the amygdala (41).

the idea that pharmacotherapy largely masks the symptoms of
PTSD rather than addressing the “conditioned fear responses” to
previous traumatic stimuli (42). Finally, there are less-common
treatments for PTSD including categories of alternative and
complementary medicine as well as TMS.

Trauma-Based Psychotherapy
The most strongly supported forms of psychotherapy used in
treatment of PTSD is trauma-focused therapy. Trauma-focused
therapies for PTSD include, “a variety of techniques most
commonly involving exposure and/or cognitive restructuring
(e.g., Prolonged Exposure, Cognitive Processing Therapy
and Eye movement Desensitization and Reprocessing)” (43).
Traditionally, patients are exposed to past traumatic events and
situations to identify their level of stress response. These events
are then paired with learned skills and coping mechanisms that
can alleviate symptoms of PTSD and alter their stress response.
Eye movement desensitization and reprocessing (EMDR) is a
form of exposure therapy that combines a cognitive component
as well as self-monitoring techniques. EMDR therapy involves an
eight-phase treatment approach that includes the reprocessing
phase where, “dual attention stimuli in the form of bilateral
eye movements, taps, or tones” are used during exposure to
traumatic events or memories to reassess how the patient deals
with these scenarios (44). EMDR has been found useful in
treatment of nightmare disorders associated with PTSD as this
therapy improved symptoms and quality of sleep (45).
Another form of therapy commonly used is stress inoculation
training (SIT) and is commonly used as a first-line alternative
therapy to trauma-based therapy and is equally efficacious
(43). SIT involves applying breathing techniques, relaxation
techniques, and other forms of cognitive restructuring when
faced with stressful or traumatic reoccurrences and memories.

Pathophysiology: HPA Axis and Sympathetic
Nervous System
The underlying symptoms that result from the deranged stress
response found in PTSD are connected to a complex integrated
adaptive system of signaling molecules comprised of hormones,
neurotransmitters, and neuropeptides. The stress response is
comprised of the HPA axis and sympathetic nervous system.
The HPA axis is regulated by negative feedback, however, in
PTSD this feedback loop is altered due to the presence of low
basal cortisol levels and raised catecholamine levels (38). There
is ongoing research attempting to explain the cause of the HPA
axis derangements including the existence of genetic variants of
glucocorticoid receptors (36). Other studies have investigated the
causes of hypocortisolism in relation to adrenal response and
activity (31). The HPA axis is modified due to the presence of
chronic stress and should continue to be a research subject for
both explaining the pathophysiology of PTSD and its utility as a
potential treatment target.

Pharmacotherapy
Pharmacotherapy is used in the treatment of PTSD and while
a number of off-label drugs are used in treatment, only
two are approved by the FDA which are paroxetine and
sertraline (46). The first line pharmacotherapy for PTSD includes
selective serotonin reuptake inhibitors (SSRIs) and serotonin and
norepinephrine reuptake inhibitors (SNRIs). More specifically,
a meta-analysis study of 37 randomized placebo-controlled
trials showed that paroxetine, sertraline, and venlafaxine were
superior in symptom relief of PTSD compared to placebo
(47). Furthermore, a post-hoc analysis suggests venlafaxine is
effective for both men and women across all subtypes of trauma
while paroxetine or sertraline were not effective across multiple
subgroups (48). Buspirone is another medication, which works
on the serotonin system, that could be used to treat PTSD. An
open trial of 8 patients was performed which showed that 7 out
of 8 of the patients had a significant reduction in symptoms as
measured by the Structured Interview for PTSD and the Beck
Depression Inventory (49).
The off-label drugs included in PTSD treatment range from
tricyclic antidepressants like amitriptyline, imipramine to other
like mirtazapine, nefazodone, phenelzine, and antipsychotics like

Current Treatment of PTSD
Current treatment for PTSD includes a wide variety of
psychotherapies and pharmacotherapy that is applied based on
clinical presentation, compliance, and severity. According to the
Veteran’s Affairs/Department of Defense (VA/DoD), American
Psychiatric Association (APA), and International Society for
Traumatic Stress Studies (ISTSS), guidelines present medications
and psychotherapy as equivalent first-line treatments (42).
However, psychotherapies tend to be more heavily relied
upon and produce longer therapeutic results compared to
pharmacotherapy alone. The reason behind this is associated to
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depolarize axons of the cortex. Axons are depolarized before the
cell bodies of neurons due to the lower threshold of activation
(58). This can lead to local changes in the cortex or secondary
and deeper structures via neuronal subcortical pathways and
neurotransmitter release (59, 60).
There are different modalities of TMS. The most commonly
used is the repetitive magnetic transcranial stimulation (rTMS)
where a regularly, repeated magnetic pulse is delivered to
exert its effects (56, 61). rTMS can fire up to tens of
pulses per second (62). Most recently, intermittent theta
burst stimulation (iTBS) has been developed which delivers
very high frequency stimulation over short periods of time.
iTBS is generally considered a form of rTMS. Other used
modalities are the simple-TMS, which uses a single magnetic
pulse delivered over the cortex, and the coupled-TMS which
uses two magnetic pulses that are separated by variable time
intervals (63).
Currently, high frequency rTMS applied to the left DLPFC, is
approved for use in treating major depressive disorder (MDD)
in patients who have failed at least one medication trial (64).
Patients showed improvement in mood, as well as improvements
in working memory, episodic verbal memory, and language
(56). Most recently, low frequency rTMS applied over the
supplementary motor area has been approved for obsessive
compulsive disorder (57).
Promising results have led to a rapid increase in research
of TMS use in neuropsychiatric disorders. Therapeutic benefits
have been shown in anxiety disorders, such as PTSD, generalized
anxiety disorder, panic disorder, and social anxiety disorder.
It can also be effective at reducing negative symptoms of
schizophrenia and improving symptoms in neurodevelopmental
disorders such as Tourette’s and autism spectrum disorder,
substance abuse disorders, brain damage, neurodegenerative
disorders such as Alzheimer’s and Parkinson’s disease, motor
stroke, and fibromyalgia (64).
TMS therapy has advantages over other forms of therapy due
to its relative safety and fewer adverse effects. However, clinicians
should be aware of adverse effects and contraindications. The
most common side effects are headaches, neck pain, and
local pain at the stimulation site (65). Pain is thought to
be related to stimulation of superficial nerves and due to
uncomfortable positioning during treatment. Headaches may be
caused by increased blood flow from local scalp stimulation
(65). Serious adverse effects are rare with seizures being the
most commonly reported from 0.1–0.6% (57, 61). The risk of
seizure is greater with high-frequency treatments and those
with intense protocols. Other neurological conditions and
medications can lower the threshold for seizures (66). Therefore,
TMS is contraindicated in patients with a history of epilepsy
and medications that lower the seizure threshold should be
titrated down or stopped. Other absolute contraindications of
TMS include any metallic devices or implants that are in
close contact to the coil. Conducting substances can induce
eddy currents when near the magnetic coils (67). Therefore,
cochlear implants are contraindications for TMS. There is
no evidence of cognitive impairment in TMS, unlike in
electroconvulsive therapy (68). TMS is a newer therapy with

risperidone and olanzapine (47, 50, 51). Prazosin is an alpha1 adrenergic receptor antagonist that can be used in nightmare
symptoms associated with PTSD (45). A placebo-controlled
study showed that prazosin, “increased total sleep time, increased
REM sleep time, and increased mean R period duration
without alteration of sleep-onset latency” (52). Nefazodone is an
antidepressant with a structure that is completely different from
SSRIs, SNRIs, tricyclic antidepressants or monoamine oxidase
inhibitors. It has been shown in one study to decrease depression,
decrease intrusive symptoms, and improve sleep in patients with
treatment refractory PTSD (53). In another study, nefazodone
also was found to not only decrease depressive symptoms but it
also improved global subjective sleep quality and a reduction in
nightmares (54).
Ketamine is another off-label drug that is being studied
for the treatment of PTSD. It is a drug that can be used
for treatment resistant depression where it is noted to have
a rapid onset with improvement of symptoms, however, the
effect seems to wear off after 1–2 weeks (55). The rationale of
using this medication in PTSD is the dampening of the NMDA
receptors, however, it is thought that it could paradoxically
increase anxiety with this mechanism of action as well (55). More
studies will need to be performed to delineate both the drug’s
safety and efficacy as well as to develop treatment protocols for
its use (55).

Alternative and Complementary Medicine
Complementary and alternative medicine (CAM) is used in
treatment of PTSD for patients that either distrust modern
psychiatric techniques or still have symptoms following
traditional therapy (46). Complementary medicine includes
practices like yoga and exercise which work together with
traditional medicine to relieve symptoms. Alternative medicine
techniques include acupuncture, animal-assisted activities or
service animals, and alternative delivery methods of treatment
such as virtual reality trauma-based therapy (46). While these
methods are not commonly used, they have shown effectiveness
in decreasing PTSD symptoms.

Transcranial Magnetic Stimulation (TMS)
TMS Overview
TMS is a noninvasive brain-stimulating technique first
introduced in 1985 (56). It has been used to help map the
cortex with associated functions and as a therapeutic tool
with increasing potential (56, 57). TMS uses the principles of
Faraday’s electromagnetism. An electric current is created that
flows through a coiled circuit. This induces a magnetic field that
is perpendicular to that current. The magnetic field travels until
reaching another electrically conductive material to induce an
electric current on that material (57).
In practice, one or two copper coils are connected to a
capacitor that provides a changing electrical current through the
coil. This coil is placed on the scalp at a particular location,
depending on the treatment. The electric current produces
a brief magnetic pulse. The magnetic field penetrates the
scalp approximately 2 cm until reaching a conductive material,
neurons in the cortex (57). An electrical signal is created to
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vs. continuous burst firing. Low frequency stimulation is <1 Hz
and has been found to decrease cortical excitability, while high
frequency stimulation is >1 Hz and increases cortical excitability.
This is created by a magnetic field that passes through the
scalp and skull creating changes to cortical and subcortical
activity in specific brain networks (2). Additionally, along with
altering TMS frequency, the duration of application can be
altered which can directly alter synaptic strength and memory
formation. For example, long-term depression (LTD) can be
induced when low frequency stimulation is used for long periods,
while high frequency stimulation for short periods will induce
long-term potentiation (LTP). LTD is defined as weakening of
the synapse, while LTP is strengthening of the synapse. These
changes are mediated with TMS due to stimulation of the
pathways and circuit changes that induce plasticity (69). The
current understanding behind this mechanism is explained by
the relationship between LTP and NMDA receptors. NMDA
receptors are cation channels that lead to activation of a calcium
sensitive signaling pathway. This activation leads to downstream
effects at the level of pre- and post-synaptic neurons and
strengthens synapses (72). Contrarily, LTD also works through
the NMDA receptor, although induced through a different
calcium flux through the channel. LTP is mediated via fast and
large increases in calcium concentration, while LTD is facilitated
through a slow and small increase in calcium concentration
following long periods of low frequency stimulation and creates
different changes to the synapse (69). These findings exemplify
how TMS settings can be altered to alter memory and plasticity,
which has clinical utility in PTSD where individuals are
significantly impaired by miscoded, intrusive memories.

more research needed for sufficient data of possible long-term
adverse effects.
TMS is a not a one-size-fits all and there are a number of
variables to account for when applying the technique. There
are inter-individual differences in anatomy and pathology which
makes application of this therapy difficult (56). Several studies
have shown variability in healthy subjects in responses to all TMS
protocols (58). More research must be completed to demonstrate
mechanism of action and reasons for variable response before
TMS can be used as an approved therapeutic tool in other
neurologic diseases (66).

NEUROBIOLOGY OF TMS
TMS has various applications and can produce motor responses,
alteration in memory, and modify executive function. Ongoing
investigations are looking into how such changes can be
explained physiologically. It has been observed that certain
modalities and settings are associated with reproducible findings
specifically with memory formation and corticospinal excitability
(69). Predictable modifications are observed as well as other
downstream effects due to the presence of neuronal network
connections. Knowledge of particular neural networks should
be used strategically. Currently, TMS is utilized primarily
focusing on superficial, cortical regions. Since deeper brain
structures are also affected, they have the potential to be used
as a target for modulation once neural networks are better
understood (70).

The Motor Response and Establishing
Target Regions
TMS can be used to create muscle contraction. Stimulation of
the motor cortex using TMS pulses provides a simple example
of how a magnetic field located transcranially can produce an
observed response. In the original study, trains of TMS pulses
were applied over the motor cortex and the hand was observed
for muscle twitches of the targeted muscle, the first dorsal
interossei. This stimulation preferentially activated interneurons
oriented in a plane parallel to the brain surface, this created
downstream effects by transsynaptic activation of pyramidal cells
which descended and projected onto spinal motor neurons (the
corticospinal tract). Activation of the motor neurons would lead
to contraction of the target muscle and was either observed
as muscle twitches or measured with electromyography of the
muscle belly (69). This observed motor response is used to help
locate the DLPFC which usually lies around a 5-6 centimeters
in front of the primary motor cortex. However, this targeting
method frequently was not able to localize the DLPFC as there
may be significant variability in functional localization for this
area within the PFC as a whole (70). Currently, localization works
best when MRI is used to directly target and visualize the region
of interest (71).

TMS Targets for Mood Disorders
The DLPFC is an important target in TMS as it is a core
component of a number of neural networks involved with
cognitive and behavioral functions. Using both high and lowfrequency rTMS, the right DLPFC has been found to be a
promising therapeutic target in mood disorders. Both high
and low frequency were found to provide benefit to patients
with PTSD even though they have opposing mechanisms of
action, as high-frequency rTMS induces cortical excitability
and low-frequency rTMS is inhibitory (73). This contradictory
finding is explained by the different effects produced by highfrequency rTMS at the cortex and downstream changes to the
amygdala. This theory relies on the current understanding that
PTSD involves a hypoactive PFC and hyperactive amygdala.
When high-frequency rTMS is applied to the right DLPFC in
PTSD patients, excitatory effects are produced at the underlying
hypoactive cortical tissue, this activation leads to subsequent
indirect inhibition of the amygdala. Modifying the activity
level of the DLPFC and amygdala assists in the treatment
of PTSD by altering memory consolidation and modulating
fear-related emotional responses. It is not fully understood
how low frequency rTMS produces favorable changes to PTSD
symptoms, however, one model explained that therapeutic effects
are observed due to partial inhibition of lateralized right-sided
hyperactivity of the DLPFC (73).

High vs. Low Frequency Stimulation
Depending on the settings and type of stimulation, TMS can
affect neuronal activity in a variety of ways. Two of the most
studied variables include high vs. low frequency, and intermittent
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CLINICAL STUDIES: EFFICACY AND
SAFETY

Effectiveness of TMS therapy is also partially determined
on the frequency of electromagnetic stimulation that is applied
during each session, measured in hertz (Hz). It has been found
that even low-frequency stimulation at 1 Hz has proved beneficial
in patients during acute treatment (17). Moreover, Kozel et
al. failed to show that there was a statistical difference in
improvement in PTSD symptoms in the 1 Hz treatment group
compared to the 10 Hz treatment group. This is contradicted
by a double-blinded controlled study by Cohen et al. in 2004
that suggested that high-frequency (10 Hz) rTMS group showed
greater therapeutic effects than the low-frequency (1 Hz) rTMS
group (16). Both groups of researchers concluded that further
work with a larger sample population would be beneficial to
determine more accurate frequencies of stimulation but found
that rTMS therapy is effective regardless of frequency level.
Other studies applying TMS have looked at combination
treatment with certain types of therapy such as prolonged
exposure (PE) therapy and cognitive process therapy (CPT).
A prospective, randomized, double-blinded, active shamcontrolled design study looked at the effects of rTMS sessions
prior to PE therapy (12). The findings suggested that patients
had no difficulty tolerating both rTMS and PE therapy but were
inconclusive of whether combination therapy was beneficial.
Additional studies with larger sample sizes would be needed to
assess further. When rTMS combined with CPT was applied,
there was significantly greater PTSD symptom reductions early
in treatment and 6 months post treatment (17). Both of these
studies reinforce the positive effect of TMS in PTSD patients
but fail to conclude that combination therapy is beneficial for
this population.

Efficacy
Overall, TMS therapy has been suggested as an effective
treatment in PTSD patients. Results of two meta-analysis showed
that TMS therapy provides an overall therapeutic effect in PTSD
patients (74). In one study, levels of active distress decreased
along with insomnia (a major symptom of PTSD) although
intrusive memories, avoidance and hypervigilance did not (18).
Another study showed that using repetitive rTMS compared to
sham rTMS treatment produced significant reductions in PTSD
symptoms from baseline (13).
Repetitive TMS isn’t the only type of stimulation that has
shown beneficial effects. In fact, a study conducted by Philip et
al. used individual theta-burst TMS (iTBS) and compared this
to sham treatment of iTBS in fifty veterans with PTSD (11).
Although these researchers used a different sub-type of TMS
therapy, results showed that at 2 weeks patients had significantly
improved social/occupational function and improved symptoms
compared to sham treatment (11). It is worthwhile to note
that two of the studies listed above are limited in following
the duration of effects of treatment. At 2 weeks of treatment,
the study by Philip et al. showed iTBS reduced symptoms
from baseline but longer effects of treatment was not followed.
The same limitation occurred with the study conducted by
Ahmadizad et al. Conversely, this limitation has been investigated
by Watts et al. where this group of researchers looked at rTMS
delivered to right DLPFC compared to sham treatment and
followed the effects up to 2 months post-treatment (13, 14). The
results of the study suggest that although rTMS was beneficial
in reducing PTSD symptoms initially, effectiveness degraded
throughout the 2 month period of follow up once treatment had
ceased (14). A contradictory conclusion is made by Boggio et al.
who showed that effects from rTMS lasted and were significant
up to 3 months following treatment (15). This raises questions
whether TMS therapy needs to be applied periodically or until
symptoms have ceased and if effectiveness is scaled in posttreatment months.
Another variable that has been addressed is the location of
which TMS therapy is applied. The double-blinded, placebocontrolled phase II trial study by Boggio et al. looked at 30
PTSD patients and examined the effects of TMS treatment to
both the left and right DLPFC and found that right-sided rTMS
induced a larger effect compared to left-sided (15). Additionally,
these researchers found that improvement in both avoidance
and hyperarousal was larger for right-sided rTMS treatment
compared to left while reexperiencing symptoms were similar
in either side of treatment. Furthermore, although application to
the right DLPFC has typically been found to be more efficacious
compared to left, the use of bilateral application (both right and
left DLPFC cannot be ruled out (13). Left sided application may
be beneficial in certain instances as Rosenberg et al. attempted to
study the left DLPFC because previous reports suggested that this
area is more associated with improvement of mood symptoms
(18). Regardless of laterality, TMS application to the DLPFC
seems to produce the most effective results in treatment of PTSD.
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Safety
While TMS therapy appears to be effective in treating patients
with PTSD symptoms, safety remains a concern. In more
recent studies mentioned above, a set of guidelines suggested
by Wasserman were used (75). Wasserman suggested following
specific criteria regarding frequency, intensity, duration, and
repetitive pulse parameters based on motor evoked potentials
(MEP) to maintain safety and efficacy. This data was based
on side effects associated with rTMS that included seizures,
headaches, scalp pain at location site, effects on hearing, and
effects on mood.

Neurological and Neuropsychological
Effects
Seizures are a known side effect that have occurred in patients
using TMS therapy. In one study, one healthy volunteer had
a secondary generalized seizure occurred causing neurological
changes that resolved within the postictal state while all
other participants (n = 10) remained unchanged (76). Before
Wasserman released his protocol for safety of rTMS, seven
seizures had been reported. The majority of patients had
no recurrence and did not have any lasting sequelae (75).
Furthermore, cognitive performance improved in all patients
following rTMS as well as reaction time and memory (76). This is
supported by Boggio et al. who found that TMS therapy to both
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TABLE 1 | Clinical Safety and Efficacy.
Author
(Year)

Groups studied and intervention

Results and findings

Conclusions

Philip et al.
(11)

Fifty veterans with PTSD received 10 days of
sham-controlled iTBS (1,800 pulses/day),
followed by 10 unblinded sessions. Studiers
measured retention rates, changes in PTSD
symptoms (clinical and self-rated), quality of
life, social/occupational function, and
depression at 2 weeks of treatment.

At 2 weeks, iTBS was significantly associated w/
improved social/occupational function along w/
improved depression compared to sham treatment.
Moderate nonsignificant effect sizes were observed
on self-reported PTSD symptoms. One-month
outcomes indicated superiority of active iTBS on
clinician and self-rated PTSD symptoms, depression,
and social/occupational function.

iTBS appears to be a promising new
treatment for PTSD with clinical
improvements occurring early in treatment.
This suggests duration and time course of
iTBS therapy as further studies.

Fryml et al.
(12)

A prospective, randomized, double-blinded,
active sham controlled design combined
weekly sessions of rTMS and standard PE for 5
weeks. 8 military veteran patients received full
course of protocol-driven PE therapy and then
placed in rTMS or sham group. The goal was
determined improvement of PTSD following 5week course.

Of 12 consented patients, 8 completed therapy with
a dropout rate of 34%, suggesting patients had no
difficulty tolerating addition of rTMS to PE therapy.
Clinician-Administered PTSD Symptom scores
reflected a general nonsignificant trend toward
improvement, while comorbid patients with MDD
experienced significant antidepressant benefit with
treatment.

The pilot study demonstrates the safety
and feasibility of rTMS delivery to PTSD
patients and assesses the need for studies
with larger sample sizes to assess
treatment outcomes.

Ahmadizadeh
et al. (13)

Randomized controlled trial of bilateral,
unilateral right, or sham rTMS treatment on
Sixty-five patients w/ combat-related PTSD
symptoms.

Patients demonstrated significant PTSD symptom
reduction in the bilateral group compared to the
sham group but no significant difference between
bilateral and unilateral right groups. The unilateral
right group compared to the sham group showed
greater symptom reductions from baseline.

Bilateral and unilateral right rTMS
therapies are superior to sham rTMS but
does not support the hypothesis that
bilateral rTMS is more effective than
unilateral right sided rTMS.

Watts et al.
(14)

Twenty PTSD patients subjected to 10 rTMS
sessions delivered at 1 Hz to DLPFC or 10
sham rTMS sessions to same area. A blinded
rater assessed PTSD symptoms before
treatment, after treatment, and during a 2
month follow-up period.

TMS delivered at 1 Hz to right DLPRC results in
statistically and clinically significant improvements in
core PTSD symptoms compared with sham
treatments. Effectiveness degraded during the 2
months follow up after treatment had stopped.

This blinded sham controlled trial supports
the efficacy of 10 sessions of right DLPRC
rTMS delivered at 1 Hz for the treatment of
PTSD symptoms.

Boggio et al.
(15)

A double-blind, placebo-controlled phase II trial
with 30 PTSD patients randomly assigned to
receive active 20 Hz rTMS of right DLPFC,
active 20 Hz rTMS of left DLPFC, or sham
rTMS over 10 daily session spanning 2 weeks.
A blind rater assessed severity of core PTSD
symptoms before, during, and after treatment
protocol.

Both the 20 Hz rTMS of left and right DLPFC induced
a significant decrease in PTSD symptoms, however
right rTMS induced a larger effect compared to the
left rTMS. Additionally, there was improvement in
mood with left rTMS and a reduction in anxiety
following right rTMS. These effects were long lasting
and still significant at the 3-month follow-up.

Modulation of prefrontal cortex can
alleviate the core symptoms of PTSD and
suggests that high-frequency rTMS of
right DLPFC might be the optimal
treatment strategy.

Cohen et al.
(16)

A double-blinded controlled study with 24
PTSD patients received either rTMS at 1 Hz,
rTMS at 10 Hz, or sham rTMS administered
over 10 daily sessions for 2 weeks. PTSD
symptoms were assessed before, during and
after treatment protocol.

The 10 daily treatments of 10 Hz rTMS over the right
DLPFC had therapeutic effects for PTSD patients
and improved core symptoms. Additionally,
high-frequency (10 Hz) rTMS over the right DLPFC
alleviated anxiety symptoms in PTSD patients.

This study suggests that over 10 daily
sessions of rTMS (10 Hz) over the right
DLPFC for 2 weeks has greater
therapeutic effects than slow-frequency
(1 Hz) rTMS and sham stimulation.

Combat-related PTSD patients were
randomized using a 1:1 ratio in parallel design
to active (rTMS+CPT) vs. sham (sham+CPT)
rTMS just prior to weekly CPT for 12-15
sessions. rTMS was positioned over the right
DLPFC (1 Hz). Blinded raters evaluated patients
at baseline, after the 5th and 9th treatments,
and at 1,3 and 6 months post-treatment.

103 participants were randomized to either active
rTMS or sham rTMS. 60% completed treatment and
59% completed 6-month assessment. The
rTMS+CPT groups showed greater symptom
reductions from baseline across CPT session and
follow-up assessments.

The addition of rTMS to CPT treatment
compared to sham treatment with CPT
produced significantly greater PTSD
symptom reduction early in treatment and
was sustained up to 6 months
post-treatment.

Kozel et al.
(17)

Combat-related PTSD patients were
randomized to right prefrontal rTMS (1 Hz) vs.
rTMS (10 Hz). Treatments occurred 5 days a
week for 6 weeks with 3-week taper. Follow-up
evaluations were performed at one month and
three months.

Both groups (1 Hz and 10 Hz) had significant
improvements in PTSD and depression scores from
baseline to the end of acute treatment. The 10 Hz
group demonstrated significant improvement in
function while the 1 Hz group did not. A significant
advantage for either the 1 Hz or 10 Hz frequency
group on any of the scales was not be demonstrated.

Treatment using rTMS to the right DLPFC
in combat-related PTSD patients
significantly improves symptoms. Further
work to determine whether low or high
frequency rTMS is superior in larger
populations would need to be
demonstrated.

Rosenberg et
al. (18)

Twelve patients with comorbid PTSD and MDD
underwent rTMS to left frontal-cortex as an
adjunct to antidepressant medications.

75% of patients had a clinically significant
antidepressant response after rTMS. Improvements
were seen in anxiety, hostility and insomnia but
minimal improvements in PTSD symptoms.

This study shows that lDLPFC rTMS could
be effective in treating depression
associated with PTSD patients.

(Continued)
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TABLE 1 | Continued
Author
(Year)

Groups studied and intervention

Results and findings

Conclusions

Wilkes et al.
(19)

Retrospective chart review of 77 patients who
received and completed rTMS treatment with
refractory depression and PTSD symptoms
rTMS was given for 6 weeks along with weekly
psychiatric assessments which included the
completion of BDI and PCL

52% at completed trials o three or more
antidepressants
44% experienced a reduction of ≥10 points on BDI
38% experienced a reduction of greater than or
equal to 10 points on PCL

rTMS may produce a reduction in
symptoms of both depression and PTSD
in patients with refractory depression and
comorbid PTSD and may be a useful
alternative to treatment

Meta-analysis of studies regarding TMS for the
treatment of PTSD Search included studies
from major online databases from inception to
September 15, 2020

Overll effect size of d = 1.17, 95% CI [ 0.89–1.45] for
TMS as a treatment fot PTSd
Significantly larger treatment effect for high frequency
TMS (d = 1.44) compared with low frequency
(d = 0/0.27) p = 0.006
No significant difereten was found between TMS
targeting the left DLPFC and right DLPFC

TMS can be an effective treatment for
PTSD but more research is required to
understand the neurological mechanism of
TMS on specific PTSD symptoms

Systematic review of 13 studies including
549 participants Compared rTMS vs. sham,
high frequency vs. low frequency rTMS on
posttreatment PTSD scores

rTMS was superior when compared to sham in
reducting PTSD symptoms (SMD = −0.13, 95% CI
[−2.10−0.15])
High frequency rTMS was associated with slightly
inporved outcomes when compar to low-frequency
rTMS (SMD = −0.019, 95% CI {−0.19–1.00])

rTMS could be an effective treatment
for PTSD quality of evidence was rated as
very low due to small sample sizes,
treatment heterogeneity, inconsistent
results, and an imprecise pooled effect
More research is required tfor
this treatment

Belsher et al.
(20)

Effects on Mood

the right and left DLPFC is safe and not associated with declines
in cognition (15).

Speech arrest and laughter has been observed in healthy subjects
receiving rTMS stimulation (77). Other studies have noted a
similar coexisting relationship between these two side effects in
epileptic and hemiparetic patients receiving TMS as well (67).
Crying has also been observed in TMS therapy although this is
rare (75). Overall, effects on mood are transient and fail to persist
long term.
Wilke’s et al. looked at the impacts of rTMS on refractory
depression and Comorbid PTSD symptoms in veterans (19).
This was a retrospective chart review of 77 patients who
received rTMS between January 1, 2010 and October 31,
2016. The patients received rTMS for 6 weeks along with
weekly psychiatric assessments which included completed Beck’s
Depression Inventory (BDI) and PTSD checklist (PCL). 52% of
patients had copleted trials of three or more antidepressants prior
to treatment. Both BDI and PCL scores were significantly lower at
the end of rTMS treatment when compared to the baseline scores
obtained pretreatment (19). The mean differences for BDI and
PCL were significant at 15, 30, and 45 days after rTMS treatment
was initiated (p < 0.001). 44% of patients had a reduction greater
than or equal to 10 points on the BDI and 38% experienced a
reduction of the same amount on PCL (19).

Headaches
Headaches are a common side effect associated with rTMS
therapy as stimulation occurs and affects the nerves and muscles
of the skull at the application site. This causes a discomfort that
can be significant for individuals and lead to persistent muscle
tension-type headaches (75).
Frequency and intensity are the most common factors
associated with headaches from therapy (77). This is
substantiated in recent studies as the most common side
effect (11). Treatment is simple with mild analgesics and will
subside usually without persisting longer term effects (75).

Scalp Pain
Eddy currents induced in metal surface EEG electrodes located
near a stimulating coil can cause heating and skin burns during
rTMS which can be uncomfortable for most patients (78). Scalp
pain at the location site is noted as one of the most common side
effects of TMS therapy (11). Following the use of Wasserman’s
safety protocols, this rarely occurs (17).

Meta-Analysis and Systematic Reviews

Effects on Hearing

A meta-analysis performed looked at PTSD mood outcomes
with the use of TMS (81). This was a literature search of
major online databases from inception to September of 2020
which primarily searched for studies using TMS to treat
PTSD. The authors found an overall effect size of d = 1.17,
95% CI [0.89–1.45] in regards to TMS as a treatment for
PTSD (81). An analysis of moderators shows that was a
significantly larger treatment effect for high-frequency TMS

Counter et al. noted that exposure to single-pulse TMS lead
to permanent increases of auditory threshold and transient
increases in human subjects (79). This was contradicted in
another study where no hearing loss was noted in subjects
exposed to single-pulse TMS (80). Regardless, foam earplugs have
been suggested as a remedy when using TMS therapy and have
limited hearing issues as a side effect.
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These include dysregulation of the HPA axis, neural networks,
and the relationship between DLPFC and amygdala in memory
and fear learning. Although further research and understanding
is needed, these theories are promising in the application of TMS
as a treatment of PTSD.
To maximize therapeutic potential and minimize possible
adverse effects, TMS parameters and delivery of the therapy
for PTSD will need to be established. Deciding on the optimal
target region and application settings will be required, as TMS
has opposing effects when administered at different frequencies
and pulse patterns. Additionally, as TMS will be used clinically,
determining the number of doses and time of delivery will be
required for creating an effective treatment regimen. Finally,
more research is required in the investigation of PTSD and TMS
to understand how the technology can be applied for treating the
invasive symptoms of the disorder.
Along with understanding PTSD, the mechanism behind
TMS also requires further investigation. Resistant depression
has been treated with TMS and therefore it is worth applying
the technology for the treatment of PTSD. Initial research
has produced short-term successes, showing a reduction in
symptoms and overall therapeutic effects in PTSD patients.
However, many of the studies have been weak due to sample
size or length of the study, with some repeat studies producing
contradictory results. There is also no evidence out there
regarding the concurrent use of psychotropic medications,
which is considered part of the standard of care for PTSD,
and with the use of TMS. More research will need to be
done with larger sample sizes over longer periods of time to
strengthen results.

(d = 1.44) compared with low frequency (d = 0.72) with a
p-value of 0.006. There was no significant difference between
whether TMS targeted the DLPFC and right DLPEC. Larder
treatment doses were not associated with stronger treatment
effects (81).
A systematic review of studies was performed by Belsher et
al. in 2021 which looked at the use of rTMS for PTSD (20). This
review looked at 13 studies with 549 participants and the authors
compared the effects of rTMS verus sham, high-frequency
verses low-frequency rTMS on posttreatment PTSD scores using
calculated standardized mean differences (SMD). The authors
concluded that at posttreatment rTMS was superior to shame
in reducing PTSD symptoms (SMD = −1.13 95% CI [−2.10–
−0.15]) (20). However, they also concluded that the quality of
their analysis was rated as very low due to small sample sizes,
treatment heterogeneity, inconsistent results, and an imprecise
pooled effect. High-frequency rTMS was associated with slightly
improved outcomes compared to low-frequency rTMS on PTSD,
however, this was also imprecise. They concluded that further
research is required to further delineate the effects of rTMS on
PTSD (20). Table 1 is a summary of the studies discussed in this
section.

CONCLUSION
Early studies have shown encouraging results for the use of TMS
as a therapeutic tool in treating PTSD. Its use appears to be
relatively safe with few adverse effects and is approved by the FDA
for the treatment of refractory MDD. However, more data needs
to be gathered to confidently use TMS as an approved treatment
protocol for PTSD.
A limitation to applying this technique is that PTSD is not
fully understood, as seen by the evolving definition of PTSD in
the latest updates of the DSM. In addition, there are multiple
theories that explain the underlying mechanism behind PTSD.
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